Phase I single and multiple-dose safety and pharmacokinetic clinical studyof bowman-birk inhibitor concentrate, WS #42
Ended Definitive Contract Awarded Last action
- Contract number
- 00261200209D261025118
- Awardee
-
The Trustees Of The University Of Pennsylvania UEI GM1XX56LEP58
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,500,348
Award facts
- Contract value 24% obligated
-
- $6,031,113.00 Current, with exercised options
- $6,199,624.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer
- Pricing
- Cost No Fee
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $168,511 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $200,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $536,837 | |
| Original award | $595,000 |
Show all 11
About this award
This contract award to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, is for a Phase I single and multiple-dose safety and pharmacokinetic clinical study of Bowman-Birk Inhibitor Concentrate, with a total ceiling value of $6,199,624.00. The contract is a definitive Cost No Fee contract with a period of performance through December 29, 2009. The place of performance is in Philadelphia, PA. This contract award does not have a set-aside designation. The clinical practices of the University of Pennsylvania are providing research and clinical trial services to the federal government under this contract. The University of Pennsylvania is a renowned private research university with extensive expertise in biomedical research and healthcare delivery, supporting federal priorities through both contract awards and grants.
Quick answers
Who was awarded contract 00261200209D261025118?
00261200209D261025118 was awarded to The Trustees Of The University Of Pennsylvania by National Cancer Institute (National Institutes of Health) on September 15, 2002.
How much is contract 00261200209D261025118 worth?
The government has obligated $1,500,348 on 00261200209D261025118. Its current value, with exercised options, is $6,031,113. Its potential value, with all options, is $6,199,624.
Was contract 00261200209D261025118 competed?
The extent of competition for 00261200209D261025118 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award